All Stories

  1. Squalene-adenosine nanoparticles enhance cardioprotection in myocardial infarction: Efficacy and mechanistic insights
  2. Intranasal delivery of lipid-based nanoparticles for the treatment of neurodegenerative diseases: advances, challenges and future perspectives
  3. Surface decoration of solid lipid nanoparticles with cyclic RGD peptides for precision therapy in high-risk neuroblastoma
  4. Targeting neuroinflammation in Parkinson's Disease: Immunomodulatory effects of a Hyaluronic Acid-Based Nanoreinforced Hydrogel Loaded with GDNF and Mesenchymal Stem cells
  5. 3D-printed polycaprolactone scaffolds functionalized with poly(lactic-co-glycolic) acid microparticles enhance bone regeneration through tunable drug release
  6. Targeting tumor microenvironment with RGD-functionalized nanoparticles for precision cancer therapy
  7. RNA delivery technologies: From concept toward the clinic
  8. RNA-loaded nanoparticles for the treatment of hematological cancers
  9. Fifty years of sciences with Patrick Couvreur
  10. Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics
  11. Correction: Biosafety evaluation of etoposide lipid nanomedicines in C. elegans
  12. Biosafety evaluation of etoposide lipid nanomedicines in C. elegans
  13. Lipid nanoparticles for siRNA delivery in cancer treatment
  14. Self-assembled lipid–prodrug nanoparticles
  15. Cardiac tissue engineering for myocardial infarction treatment
  16. Hydrogels for brain repair: application to Parkinson’s disease
  17. Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering
  18. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system
  19. Special issue on the latest advances in regenerative medicine and cancer using drug delivery systems
  20. In vivo biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99 m: Comparison of administration routes in mice
  21. Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors: A comparative study
  22. Decoration of Squalenoyl‐Gemcitabine Nanoparticles with Squalenyl‐Hydroxybisphosphonate for the Treatment of Bone Tumors
  23. Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
  24. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment
  25. Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction
  26. Optimization of a GDNF production method based on Semliki Forest virus vector
  27. Special Issue “A perspective of drug delivery and translational research in Europe”
  28. Extracellular Vesicle-Based Therapeutics for Heart Repair
  29. SPION and doxorubicin-loaded polymeric nanocarriers for glioblastoma theranostics
  30. Morphology, gelation and cytotoxicity evaluation of D-α-Tocopheryl polyethylene glycol succinate (TPGS) – Tetronic mixed micelles
  31. Improving the genistein oral bioavailability via its formulation into the metal–organic framework MIL-100(Fe)
  32. Sorting hidden patterns in nanoparticle performance for glioblastoma using machine learning algorithms
  33. Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma
  34. Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice
  35. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy
  36. Nanomedicine and drug delivery systems in cancer and regenerative medicine
  37. Co-encapsulation of superparamagnetic nanoparticles and doxorubicin in PLGA nanocarriers: Development, characterization and in vitro antitumor efficacy in glioma cells
  38. A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine
  39. Long-Term Engraftment of Human Cardiomyocytes Combined with Biodegradable Microparticles Induces Heart Repair
  40. Micro- and nanotechnology approaches to improve Parkinson's disease therapy
  41. Therapeutic Opportunities in Neuroblastoma Using Nanotechnology
  42. Advances in Parkinson’s Disease: 200 Years Later
  43. Biocompatible porous metal-organic framework nanoparticles for gentamicin vectorization
  44. NRG1 PLGA MP locally induce macrophage polarisation toward a regenerative phenotype in the heart after acute myocardial infarction
  45. Nanomedicines for Pediatric Cancers
  46. Oral nanoencapsulated ET causes regression of lung metastases in models of osteosarcoma
  47. Heart tissue repair and cardioprotection using drug delivery systems
  48. Visualization of hybrid gold-loaded polymeric nanoparticles in cells using SEM
  49. Special Issue: Pharmaceutics and Drug Delivery in Spain
  50. Breaching barriers in glioblastoma: Targeted drug delivery
  51. Breaching barriers in glioblastoma: novel treatment approaches
  52. Hydrogel based approaches for cardiac tissue engineering
  53. Cytokine-loaded PLGA and PEG-PLGA microparticles showed similar heart regeneration
  54. Special issue on biomaterials for tissue engineering
  55. Effectiveness of nanoencapsulated methotrexate against osteosarcoma cells
  56. Transplantation of ADSC combined with neuregulin-microparticles promotes efficient cardiac repair
  57. The combination of DOX and ET is likely to be effective against osteosarcoma.
  58. Nanotechnology-based drug delivery systems for Alzheimer's disease management
  59. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys
  60. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein
  61. Clinical advances of nanocarrier-based cancer therapy and diagnostics
  62. Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion
  63. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation
  64. Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease
  65. Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies
  66. Reformulating cyclosporine A (CsA): More than just a life cycle management strategy
  67. Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems
  68. A simple approach to obtain hybrid Au-loaded polymeric nanoparticles with a tunable metal load
  69. Lipid nanoparticles for osteosarocma therapy
  70. Tracking the in vivo release of bioactive NRG from PLGA and PEG–PLGA microparticles in infarcted hearts
  71. Lípidos nanoparticles for oral CyA administration
  72. Polymeric Electrospun Scaffolds: Neuregulin Encapsulation and Biocompatibility Studies in a Model of Myocardial Ischemia
  73. Heart regeneration after myocardial infarction using synthetic biomaterials
  74. A Zn azelate MOF: combining antibacterial effect
  75. Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
  76. Lipid nanoparticles protect from edelfosine toxicity in vivo
  77. Edelfosine Lipid Nanoparticles Overcome Multidrug Resistance in K-562 Leukemia Cells by a Caspase-Independent Mechanism
  78. Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
  79. In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
  80. Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy
  81. Cytotoxicity of nanoscaled metal–organic frameworks
  82. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration
  83. Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia
  84. Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
  85. Efficacy of edelfosine lipid nanoparticles in breast cancer cells
  86. Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia
  87. Injectable alginate hydrogel loaded with GDNF promotes functional recovery in a hemisection model of spinal cord injury
  88. A simple and robust high-performance liquid chromatography coupled to a diode-array detector method for the analysis of genistein in mouse tissues
  89. Adipose-derived stem cells combined with Neuregulin-1 delivery systems for heart tissue engineering
  90. Vascular endothelial growth factor‐loaded injectable hydrogel enhances plasticity in the injured spinal cord
  91. Biographies featuring the special issue editors Dr. M.N.V. Ravi Kumar, Dr. María J. Blanco-Prieto and D.N. Waterhouse
  92. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines
  93. Nanotheraputics
  94. Gentamicin-Loaded Nanoparticles Are Effective against Brucella melitensis
  95. Ultra high performance liquid chromatography–tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems
  96. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system
  97. Editorial
  98. PEGylated-PLGA microparticles containing VEGF for long term drug delivery
  99. Brain Drug Delivery Systems for Neurodegenerative Disorders
  100. Lipid nanoparticles for cancer therapy: state of the art and future prospects
  101. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin
  102. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles
  103. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia
  104. Vascular Endothelial Growth Factor-Delivery Systems for Cardiac Repair: An Overview
  105. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma
  106. Development and validation of ultra high performance liquid chromatography–mass spectrometry method for LBH589 in mouse plasma and tissues
  107. Angiogenic therapy for cardiac repair based on protein delivery systems
  108. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease
  109. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections
  110. High Loading of Gentamicin in Bioadhesive PVM/MA Nanostructured Microparticles Using Compressed Carbon-Dioxide
  111. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia–reperfusion model
  112. Lipid raft-targeted therapy in multiple myeloma
  113. In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts
  114. Drug delivery systems for potential treatment of intracellular bacterial infections
  115. Production of highly pure human glycosylated GDNF in a mammalian cell line
  116. Comparative study of A HPLC–MS assay versus an UHPLC–MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems
  117. Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson's disease
  118. Antitumor Alkyl Ether Lipid Edelfosine: Tissue Distribution and Pharmacokinetic Behavior in Healthy and Tumor-Bearing Immunosuppressed Mice
  119. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres
  120. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization
  121. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor
  122. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections
  123. Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum‐Based Chemotherapy
  124. Poly(d,l-Lactide-Coglycolide) Particles Containing Gentamicin: Pharmacokinetics and Pharmacodynamics in Brucella melitensis- Infected Mice
  125. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson
  126. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  127. Nanocarriers with Gentamicin to Treat Intracellular Pathogens
  128. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin
  129. Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method
  130. Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin
  131. Polymeric Particulates to Improve Oral Bioavailability of Peptide Drugs
  132. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography–electrospray mass spectrometry: application to cell uptake studies and characterization of drug delivery systems
  133. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres
  134. High-performance liquid–chromatographic determination of rifampicin in plasma and tissues
  135. Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography
  136. Development and validation of a liquid chromatographic method for in vitro mupirocin quantification in both skin layers and percutaneous penetration studies
  137. Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture
  138. Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters
  139. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  140. In vitro evaluation of gentamicin released from microparticles
  141. Optimization of topical cidofovir penetration using microparticles
  142. PLGA microparticles: possible vehicles for topical drug delivery
  143. Topical application of acyclovir-loaded microparticles: quantification of the drug in porcine skin layers
  144. In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres
  145. Importance of the test medium for the release kinetics of a somatostatin analogue from poly(?-lactide-co-glycolide) microspheres
  146. Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides